<>
Daraxonrasib, a RAS(ON) multi-selective inhibitor evaluated in phase 1/2 clinical trials for pancreatic cancer, faces hurdles with acquired drug resistance. Published in Nature Medicine on August 11, 2026, circulating tumor DNA analyses of 44 patients coupled with preclinical modeling reveal resistance mechanisms and point toward rational combination therapy strategies.
Understanding Acquired Resistance to Daraxonrasib Monotherapy
Monotherapies targeting these pathways often prompt tumors to adapt through secondary mutations or alternative signaling bypass tracks.
By analyzing circulating tumor DNA—fragments of genetic material shed by dying tumor cells into the bloodstream—investigators captured the genomic footprint of drug resistance as it emerged.
In Plain English: The Clinical Takeaway
Translational Modeling and Rational Combination Strategies
To move beyond the limitations observed in monotherapy, the research team combined patient ctDNA data with robust preclinical translational modeling.
Recognizing these specific escape routes allows researchers to design rational combination therapies.
| Parameter | Details from 2026 Study |
|---|---|
| Study Cohort Size | 44 patients with pancreatic cancer |
| Clinical Trial Phase | Phase 1/2 trial evaluation |
| Primary Surveillance Tool | Circulating tumor DNA (ctDNA) analysis |
| Core Journal & Date | Nature Medicine, August 11, 2026 |
Contraindications & When to Consult a Doctor
Looking Ahead in Pancreatic Cancer Care
References
- Nature Medicine. (2026). Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. doi:10.1038/s41591-026-04537-w.
